MedPath

Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Phase 4
Completed
Conditions
Acute Lymphoblastic Leukemia
First Posted Date
2007-07-02
Last Posted Date
2009-05-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
374
Registration Number
NCT00494897
Locations
🇪🇸

Hospital Central de Asturias, Oviedo, Asturias, Spain

🇪🇸

Hospital general de Castellón, Castello, Castellón, Spain

🇪🇸

Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain

and more 83 locations

Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 4
Completed
Conditions
Acute Myeloid Leukemia
First Posted Date
2007-06-20
Last Posted Date
2008-11-18
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
47
Registration Number
NCT00488709
Locations
🇪🇸

Hospital Sant Pau, Barcelona, Spain

🇪🇸

Hospital Ntra. Sra. de Sonsoles, Avila, Spain

🇪🇸

Hosptal Joan XXIII, Tarragona, Spain

and more 13 locations

SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia

Phase 4
Completed
Conditions
Myelodysplastic Syndrome
Acute Myeloblastic Leukemia
First Posted Date
2007-06-18
Last Posted Date
2008-11-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
200
Registration Number
NCT00487448
Locations
🇪🇸

Hospital Germans Trias i Pujol, Badalona, Spain

🇪🇸

Hospital Universitario La Paz, Madrid, Spain

🇪🇸

Hospital del Mar, Barcelona, Spain

and more 12 locations

2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)

First Posted Date
2007-06-06
Last Posted Date
2012-08-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
13
Registration Number
NCT00483067
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Phase 1
Terminated
Conditions
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Leukemia
Interventions
First Posted Date
2007-06-01
Last Posted Date
2012-08-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
27
Registration Number
NCT00480987
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2007-05-30
Last Posted Date
2019-02-15
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
10
Registration Number
NCT00480090
Locations
🇨🇦

University Health Network, Toronto, Ontario, Canada

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

First Posted Date
2007-05-23
Last Posted Date
2022-01-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
107
Registration Number
NCT00477412
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

ALL Adult Consortium Trial: Adult ALL Trial

First Posted Date
2007-05-21
Last Posted Date
2024-04-17
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
112
Registration Number
NCT00476190
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Children's Hospital of Boston, Boston, Massachusetts, United States

and more 12 locations

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Phase 1
Completed
Conditions
Richter's Transformation
Leukemia
Interventions
First Posted Date
2007-05-14
Last Posted Date
2013-11-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
92
Registration Number
NCT00472849
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

First Posted Date
2007-05-11
Last Posted Date
2016-03-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
93
Registration Number
NCT00472056
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath